Presence of Direct Thrombin Inhibitors Can Affect the Results and Interpretation of Lupus Anticoagulant Testing

Department of Pathology, Pritzker School of Medicine, the University of Chicago, Chicago, IL 60637, USA.
American Journal of Clinical Pathology (Impact Factor: 2.51). 11/2005; 124(4):586-93. DOI: 10.1309/7RYUN5DRK4WCH3PM
Source: PubMed


In vitro experiments were conducted to determine whether the direct thrombin inhibitors argatroban and lepirudin can interfere with the results of lupus anticoagulant (LA) testing. Concentration-response curves were generated to calculate the concentration of anticoagulant that prolongs the activated partial thromboplastin time (aPTT) to 75 seconds (2.5 times the baseline average). Corresponding concentrations of anticoagulant were added to plasma samples before running dilute Russell viper venom tests (DRVVTs) and LA-sensitive aPTTs (PTT-LAs). Because the DRVVT test system contains an antiheparin agent, DRVVT results were not prolonged in the presence of heparin. With argatroban added to normal plasma samples, neither the DRVVT percent correction of ratio nor the DRVVT test/confirm ratio were elevated, but when added to LA-positive plasma, some false-negative results were observed. Lepirudin increased the DRVVT percent correction of ratio and the DRVVT test/confirm ratio into a range that could lead to false-positive identifications of LAs. In sharp contrast to the DRVVT test system, distinction between LA-positive and LA-negative plasma samples was maintained and possibly even enhanced in the platelet neutralization procedure correction phase of the PTT-LA test system.

26 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Antiphospholipid syndrome (APLS) is among the most common acquired blood protein defects that have been identified as leading to thrombosis. This article describes the laboratory diagnosis of APLS, including the detection of lupus anticoagulants, anticardiolipin antibodies, and subtypes of antiphospholipid antibodies.
    Hematology/Oncology Clinics of North America 03/2008; 22(1):19-32, v. DOI:10.1016/j.hoc.2007.10.009 · 2.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Argatroban is a direct thrombin inhibitor approved for the treatment of heparin-induced thrombocytopenia (HIT) type II. Argatroban is predominantly metabolized in the liver. It is widely believed that no dosage adjustment is required in patients with renal insufficiency, making it a preferred agent in patients on renal replacement therapy (Reddy and Grossman, Ann Pharm 2005;39:1601-1605). The elimination half-life of argatroban is approximately 50 min. Lupus anticoagulants can cause baseline elevation of the PTT and hence it is difficult to monitor the effects of anticoagulants such as heparin, lepirudin, or argatroban in patients with antiphospholipid antibody syndrome. Heparin levels may be used as an alternative for heparin monitoring but plasma levels of argatroban are not commercially available. A chromogenic antifactor IIa assay could be useful for monitoring argatroban in the presence of a lupus anticoagulant, but it is not widely available at present. We report a patient with end-stage renal disease, maintained on peritoneal dialysis with HIT, who demonstrated a markedly prolonged half-life when treated with argatroban despite the discontinuation of therapy. This case also demonstrates the lack of guidelines for the monitoring of argatroban therapy in the presence of an underlying lupus anticoagulant.
    American Journal of Hematology 03/2008; 83(3):245-6. DOI:10.1002/ajh.21072 · 3.80 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The latest international guidelines for the laboratory diagnosis of lupus anticoagulants (LA) date back to 1995 and are in need of revision. Various patterns of practice and interpretation by clinical laboratories have altered the intent or usage of the criteria and recommendations made at that time. Moreover, various topics in the preexamination phase of LA testing (such as the role of the clinician in test ordering, the impact of direct thrombin inhibitors or oral anticoagulant therapy, and patient biologic variation) need to be considered in future guidelines. In like fashion, examination issues relating to mixing studies will need critical review. Mixing studies have been applied to a variety of low-phospholipid LA screening assays, and no uniformity or standardization exists as to how these test results should be interpreted or if in fact they are suitable for identifying weak lupus anticoagulants.
    Seminars in Thrombosis and Hemostasis 07/2008; 34(4):380-8. DOI:10.1055/s-0028-1085481 · 3.88 Impact Factor
Show more


26 Reads
Available from